Cyclacel Limited (CYCC) Reports Phase 2 Sapacitabine Data in Acute Myeloid Leukemia and Myelodysplastic Syndromes at 2009 American Society of Hematology Annual Meeting  
12/7/2009 8:48:59 AM

BERKELEY HEIGHTS, N.J., Dec. 5, 2009 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (Nasdaq:CYCC) (Nasdaq:CYCCP) ("Cyclacel" or the "Company") announced today 1-year survival data from a Phase 2 randomized trial of oral sapacitabine capsules, a novel nucleoside analogue, in elderly patients with acute myeloid leukemia (AML) and separately interim response data in myelodysplastic syndromes (MDS). The data were reported in two poster presentations at the 51st Annual Meeting of the American Society of Hematology (ASH) in New Orleans.